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Abstract: Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. 
Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. 
Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. 
Idarucizumab was approved in 2015 by the US Food and Drugs Administration and European 
Medicines Agency for reversal of anticoagulation activity in dabigatran-treated patients. This 
review briefly summarizes the experimental evidence about effectiveness and safety of idaruci-
zumab. Furthermore, we review the current recommendations and experts’ point of view about 
the use of antidotes/reversal agents in patients reporting a major bleeding event.
Keywords: anticoagulant drugs, non-vitamin K antagonist oral anticoagulants, reversal agents, 
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Introduction
In 2009 the introduction of non-vitamin K antagonist oral anticoagulants (NOACs) 
in the market as an effective and safer alternative for the prevention of thromboem-
bolic events in atrial fibrillation (AF) patients1 and the treatment and prevention 
of recurrences in patients with venous thromboembolic events (VTE)2 drastically 
changed the current pharmacopeia and routine clinical treatment of these two 
conditions. Dabigatran etexilate (aDabiFab) is the only direct thrombin inhibitor 
among the authorized NOACs and was the first one to be demonstrated more 
effective and safer than warfarin for AF3 and has a similar efficacy and safety for 
VTE patients.4
Despite several practical aspects that favor NOACs over warfarin (no need of 
continuous laboratory monitoring, limited drug–drug interactions, no food interac-
tions, fixed-dose regimen, predictable anticoagulant activity, etc.), the absence of 
specific antidote and reversal agents has been a significant caveat to widespread use 
of these drugs.5,6 In order to face this issue, in the last years several companies started 
developing antidotes/reversal agents for NOACs.6 Among them, idarucizumab is a 
specific reversal agent for dabigatran and is also the first one to receive approval from 
the US Food and Drugs Administration (FDA) and European Medicines Agency in 
2015 (Table 1).
Idarucizumab was tested in two different randomized clinical trials,7–9 which 
demonstrated it to be an effective and safe reversal agent. This narrative review aims 
to describe the main characteristics of idarucizumab and summarize the most relevant 
evidence about its use in patients receiving dabigatran for thromboprophylaxis in those 
affected with AF and VTE.
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Mechanism of action
Idarucizumab is a humanized monoclonal antibody fragment 
specifically and potently inhibiting aDabiFab. It neutralizes 
dabigatran activity in a 1:1 stoichiometric relation in both 
in vitro and in vivo contexts (Figure 1; Table 1).10
The original molecule has been produced from dabigatran-
hapten immunized mice. After that, the antibodies were 
humanized removing the variable regions from both heavy 
and light mouse antibodies’ chains and hybridized with 
human IgG constant regions. The variable region of the 
Fab has been humanized through a design and screening 
process.10
In the original study, the parental mouse and humanized 
Fab antibodies showed similar in vitro inhibitory activity 
and clotting times, after the presence of dabigatran was 
reduced to baseline at antibody concentrations .10 nM, 
indicating complete neutralization of dabigatran at equimolar 
concentrations of dabigatran and aDabiFab.10
The inhibition activity is due to the noncompetitive bind-
ing of dabigatran to a concave region present in the interface 
of the aDabiFab variable domain. Hydrophobic interactions, 
H-bonds, and a salt bridge mediate the binding. Idaruci-
zumab binds dabigatran with a 350-fold higher affinity than 
thrombin (Table 1).10 In vivo experiments confirmed in vitro 
results, with a complete reversal of anticoagulant activity 
within 1 minute of injection in the mice, sustained during 
the subsequent 25 minutes, despite the continuous infusion 
of further dabigatran.10
Despite the similarities between aDabiFab and thrombin 
in recognition and binding of dabigatran, aDabiFab did 
not show any thrombin-like activity, and in the absence of 
dabigatran, in vitro studies did not show any effect of the 
compound on the coagulation pathways.10
Experimental evidence
So far, idarucizumab has been tested in two studies.7–9 The 
first one was a randomized, placebo-controlled, double-
blind Phase I trial. In this study, 47 healthy male volunteers 
aged 18–45 years with normal body mass index and no 
relevant health conditions were enrolled to be allocated in 
four idarucizumab sequential dose groups (1 g, 2 g and 4 g 
[as one 5 minutes intravenous infusion] and 5 g plus 2.5 g 
[as two 5 minutes intravenous infusions 1 hour apart]) and 
randomized to receive idarucizumab or placebo in a 3:1 
ratio. All the subjects received dabigatran 110 mg twice 
Figure 1 idarucizumab and dabigatran in the context of the hemostatic process.
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Table 1 Main characteristics of idarucizumab
Feature Idarucizumab
Structure Humanized Fab fragment
Molecular mechanism Noncompetitive binding
(350-fold higher affinity than thrombin)
Route of delivery Two 50-mL intravenous bolus infusions 
15 minutes apart, equal to 5 g of drug
Regulatory aspects Approved by FDA and eMA
Latency immediate onset of reversal
Duration of effect 12–24 hours
Studies NCT01688830,7 NCT02104947 (REVERSE-AD)8,9
Costs $3,662.06 (US) – €3,909.91 (EU) per unit
Abbreviations: eMA, european Medicines Agency; FDA, Food and Drug Admini-
stration.
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daily for 3 days. At day 4, after the last dabigatran dose, the 
subjects allocated in each group received the randomized 
treatment.7
After receiving dabigatran, all the subjects showed a 
consistent increase in all coagulation tests examined (diluted 
thrombin time [dTT], ecarin clotting time [ECT], thrombin 
time, activated partial thromboplastin time [aPTT], activated 
clotted time). All idarucizumab doses showed an immediate 
and complete reversal of the dabigatran-induced increase 
in dTT, which was reduced to less than the upper limit of 
normal and extremely close to the baseline values.7 The 
reduction in dTT was consistent for all the idarucizumab 
doses, except for 1 g which showed a new increase in dTT 
after finishing the infusion. Similar evidence was obtained 
for the other tested essays.7 A dose-dependent effect was 
found when examining the ratio reduction in the four doses 
tested. Indeed, 1 g idarucizumab infusion resulted in a 74% 
dTT reduction compared with placebo infusion, 2 g in a 94% 
reduction and so on progressively up to 99% reduction with 
5 g plus 2.5 g. Furthermore, the infusion of idarucizumab 
showed normalization of other coagulation indexes, and 
completely canceled any effect of dabigatran.7
The main Phase III study to test efficacy and safety of 
idarucizumab in reversing dabigatran anticoagulant effect 
has been the Reversal Effects of Idarucizumab on Active 
Dabigatran (RE-VERSE AD).8,9,11 Results of the RE-VERSE 
AD were firstly published in 2015 on a smaller cohort while 
the study was still ongoing,8 which led to FDA approval, 
while full results of the study, on the entire cohort, were 
published in 2017.9 We reported data mostly based on the 
full cohort report.
In this multicenter, prospective, single cohort study, 
503 patients receiving dabigatran were enrolled to receive 
5 g of intravenous idarucizumab in two distinct boluses, no 
more than 15 minutes apart. The primary efficacy end point 
was the maximum percentage of reversal of the anticoagu-
lation effect of dabigatran up until 4 hours after the second 
idarucizumab infusion.9 After the infusion, dTT, ECT, and 
aPTT were sequentially tested to evaluate the reversal effect. 
Also, the concentration of unbound dabigatran was tested. 
All the patients enrolled were divided into two groups: all the 
patients presenting with an uncontrollable or life-threatening 
major bleeding were enrolled in group A and all those need-
ing surgery or another invasive procedure that could not 
be delayed and therefore requiring complete and normal 
hemostasis were enrolled in group B.
Both the groups were substantially similar regarding 
the baseline characteristics, dTT, and ECT, which were 
prolonged in more than 90% of patients (461 out of 503) at 
study entry, went back to normal values immediately after 
the first infusion, with a percentage of reversal within the 
4 hours from infusion equal to 100%. The reversal was sus-
tained up to 24 hours.9 The percentage of unbound dabigatran 
remained consistently ,20 ng for 24 hours in most of the 
patients. In 23% of patients, a reappearance of dabigatran 
levels .20 ng occurred after 12 hours, with 67 of them 
having elevated levels at 24 hours. In 10 of these patients, 
being included in group A, the reappearance of unbound 
dabigatran was associated with relapse in bleeding.9
Among 203 patients in group A, for which the assess-
ment of bleeding cessation could have been performed, 134 
(67.7%) of them had the bleeding cessation confirmed within 
24 hours, with a median (95% CI) time to hemostasis of 
2.5 hours (2.2–3.9 hours).9 Different from the entire cohort, 
data coming from the initial report showed a longer median 
time to bleeding cessation (11.4 hours).8 For the patients in 
group B, periprocedural hemostasis was considered as normal 
in 184 (93.4%) patients, while no patients had severely 
abnormal hemostasis.9
Regarding the safety of idarucizumab infusion, throm-
botic events occurred in 4.8% (24 patients) of the entire 
cohort of 503 patients. In only three cases, the thrombotic 
event was fatal. In the follow-up observation, 30- and 90-day 
mortality rates were similar between the two groups (13.5% 
and 12.6% for groups A and B, respectively; 18.8% and 
18.9% for groups A and B, respectively).9
Clinical usefulness and impact on 
real world
Several data report that the magnitude of the fear of a major 
bleeding event occurrence is fourfold higher than the fear 
of any thromboembolic event for any physician prescribing 
oral anticoagulant therapy.12 The absence of any possible 
direct reversal agent has been postulated as a possible caveat 
to the use of NOACs.5 Theoretically speaking, several non-
specific reversal strategies can be used even with NOACs 
(prothrombin complex concentrate, recombinant FVIIa, etc).6 
Notwithstanding, to create something that could resemble the 
role of vitamin K in reversal of warfarin-related anticoagula-
tion, clinical research started to develop several possible spe-
cific reversal agents, even though so far only idarucizumab 
was authorized for clinical use, while other drugs are still in 
the premarket phase despite some relevant studies.13,14
So far, only scarce and sparse data have been published 
about its use in daily clinical routine.15 Only small case 
series have been documented with not enough evidence 
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to understand to what extent the use of idarucizumab can 
effectively affect the clinical course of patients presenting 
with acute bleeding or with a need for immediate reversal for 
urgent surgery. In a small retrospective review, the authors 
clearly stated that it remained unclear in which clinical situ-
ations idarucizumab would be clinically indicated.15
In the recent 2016 European Society of Cardiology (ESC) 
guidelines on management of AF patients, the management 
of bleeding events in anticoagulated patients was discussed.16 
In the occurrence of moderate–severe bleeding in patients 
taking NOACs, the guidelines firstly recommend to manage 
patients’ conditions in order to stabilize the hemodynamics 
and treat (if possible) the causes of bleeding, as well as the 
use of oral charcoal if the assumption of the drugs is quite 
recent.16 Only in the occurrence of severe or life-threatening 
bleeding, the guidelines recommend the use of specific anti-
dotes/reversal strategies.16
These recommendations were derived from the joint 
position paper of the ESC Working Group on Cardiovas-
cular Pharmacotherapy and the ESC Working Groups on 
Thrombosis.17 In this position paper, a group of experts 
revised all the available evidence related to the risk of 
bleeding in patients taking NOACs and about effectiveness 
and safety of the available NOACs’ reversal agents. The 
experts’ consensus established that while the effectiveness of 
these agents is very likely, in particular for idarucizumab, in 
effectively reversing the anticoagulant effect of the various 
NOACs, it is not clear if this reversal can significantly affect 
the occurrence of adverse clinical events.17 Furthermore, it 
is still unclear whether the sudden termination of antico-
agulation in patients with a high thromboembolic risk may 
imply an increase in the risk of thromboembolic events,17 
which could then jeopardize the final net clinical benefit. 
In the case of idarucizumab, we should also take into con-
sideration the very high price of the drug, and in this light 
future cost-effectiveness evaluation would be needed to 
understand in what conditions its use is justified concerning 
cost-effectiveness. All these considerations made the expert 
consensus deliberate about the exclusive use of reversal 
agents in specific situations, after a careful consideration of 
various pharmacological and clinical issues, and only for 
those patients in whom every other measure had failed.17 
This attitude is also justified by the relatively low incidence 
of severe/life-threatening bleeding events with NOACs,18 as 
well as the short half-life of these agents.
A similar approach has been suggested in the “American 
College of Cardiology Expert Consensus Decision Pathway on 
Management of Bleeding in Patients on Oral Anticoagulants”, 
in which the use of reversal agents was recommended only 
when the bleed occurred to a critical site or in the case of 
life-threatening bleeding.19 This document, differently from 
the other mentioned above,17 also supports the use of routine 
laboratory tests to evaluate the NOAC circulating levels 
indirectly. Even if some indications can be drawn in patients 
taking dabigatran, in particular from aPTT levels, normal 
levels of aPTT cannot exclude on-therapy levels; therefore, 
the usefulness of routine laboratory test in the evaluation of 
NOACs patients actively bleeding is limited.19
Taking into consideration all the evidence reported, we 
believe that several considerations could be drawn.
Firstly, based on the experience in the use of vitamin K 
to treat patients who received vitamin K antagonist overdose 
or who presented with clinically relevant bleeding, it appears 
that in the past, physicians much likely overestimated the 
need for some specific antidotes for NOACs. Secondly, the 
clinical measures to manage and contain major bleeding 
effects are not considered valuable procedures to treat these 
patients, in the general physicians’ belief. Thirdly, possibly 
a strong misunderstanding exists between what the words 
“antidote” and “reversal” mean. According to Collins dic-
tionary (https://www.collinsdictionary.com) “an antidote is 
a chemical substance that stops or controls the effect of a 
poison”; conversely, to reverse is defined as “to turn or set 
in an opposite direction, order, or position” or alternatively 
“to change into something different or contrary; alter com-
pletely”. Most likely, based on the reported definitions, the 
physicians do not merely need an antidote or a reversal agent, 
since the real need is to provide an effective treatment for 
stopping a major bleeding event. Indeed, even if an antidote 
stops the anticoagulant activity, it does not control the active 
bleeding; conversely, to name a substance as a reversal 
agent, it should restore the coagulation activity with the risk 
to result in a procoagulant effect, as the experts underlined. 
Considering the data coming from the RE-VERSE AD, we 
can state that idarucizumab consistently inhibits dabigatran 
anticoagulant activity, but the question of how much this 
results in a significant benefit on major outcomes, as a con-
sequence of its use in the real world, is still open.
All the evidence point out that a change in physicians’ 
view is needed on the management of actively bleeding 
anticoagulated patients. Indeed, even though an active sub-
stance “blocking” the anticoagulant activity (a blocker, not 
an antidote or a reversal agent) could represent an important 
aid for some specific situations, the most important approach 
in actively bleeding patients is to sustain the patients’ condi-
tions and physically “constrain” the bleeding. Furthermore, in 
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those patients undergoing urgent procedures, while available 
data from the real world so far seem to report large underuse,15 
a recent review of NOACs from the surgical point of view 
underlines how the use of antidotes/reversal agents is limited 
to very few patients.20 This document underlines that the main 
issue for each surgeon is to precisely measures the patient’s 
ongoing anticoagulant activity, to reassure the operator 
before to proceed with a surgical procedure, even an urgent 
one. Given the lack of availability of these tests on a large 
scale, a valid approach that could be suggested is to delay as 
much as possible the surgery, waiting long enough to be sure 
that the pharmacological activity is ceased.20 Unfortunately, 
this approach in some cases could be not feasible or quite 
risky, and further data are needed to better guide clinical 
decision-making.
Notwithstanding, keeping in mind all the limitations we 
underlined above, we think that a number of specific situa-
tions can be identified, in which it would be reasonable to 
consider using idarucizumab to control the anticoagulation 
activity (Box 1), adhering to the guidelines and expert posi-
tions recommending its use exclusively in extremely severe 
bleeding and critically clinical conditions.
All these aspects, together with the absence of strong 
data on the clinical effectiveness in reducing major adverse 
events, as well as the risk of rebound increased thromboem-
bolic risk, support the claim for further stronger evidence 
clarifying these aspects.21
Conclusion
Idarucizumab has been proved to reverse rapidly, effectively, 
and consistently anticoagulant activity in dabigatran-treated 
patients. Despite the strong evidence pointing out the 
effectiveness and safety of idarucizumab, strong data on 
patient outcomes are still needed to better target the use of 
idarucizumab, according to specific high-risk conditions, 
as well as for other antidotes/reversal agents, in the context 
of real-world clinical practice.
Disclosure
MP received consulting fees from Boehringer Ingelheim 
outside the submitted work; GB received personal fees from 
Medtronic, Boston, Boehringer and Biotronik, outside the 
submitted work. The authors report no other conflicts of 
interest in this work.
References
 1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy 
and safety of new oral anticoagulants with warfarin in patients with 
atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 
383(9921):955–962.
 2. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, 
Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute 
venous thromboembolism: a systematic review and meta-analysis. 
Thromb Res. 2014;134(4):774–782.
 3. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus war-
farin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): 
1139–1151.
 4. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin 
in the treatment of acute venous thromboembolism. N Engl J Med. 
2009;361(24):2342–2352.
 5. Schulman S. New oral anticoagulant agents – general features and out-
comes in subsets of patients. Thromb Haemost. 2014;111(4):575–582.
 6. Proietti M, Lip GYH. Antidotes to non-vitamin K oral anticoagulants: 
necessary or not? Expert Opin Pharmacother. 2015;16(11):1573–1576.
 7. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy 
of idarucizumab for the reversal of the anticoagulant effect of dabigatran 
in healthy male volunteers: a randomised, placebo-controlled, double-
blind phase 1 trial. Lancet. 2015;386(9994):680–690.
 8. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran 
reversal. N Engl J Med Overseas Ed. 2015;373(6):511–520.
 9. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran 
reversal – full cohort analysis. N Engl J Med. 2017;377(5):431–441.
 10. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabiga-
tran: functional and structural characterization. Blood. 2013;121(18): 
3554–3562.
 11. Pollack CV, Reilly PA, Bernstein R, et al. Design and rationale for 
RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal 
agent for dabigatran. Thromb Haemost. 2015;114(1):198–205.
 12. Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. 
Adherence to oral anticoagulant therapy in patients with atrial fibrilla-
tion. Focus on non-vitamin K antagonist oral anticoagulants. Thromb 
Haemost. 2017;117(2):209–218.
 13. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the 
reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25): 
2413–2424.
 14. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of 
the non-vitamin K oral anticoagulants. Europace. 2016;18(7):955–964.
 15. Ebinger J, Granger CB, Zhu A, Chang A, Henry TD. Idarucizumab since 
FDA approval: use in the real-world. Am Heart J. 2017;193:93–94.
 16. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for 
the management of atrial fibrillation developed in collaboration with 
EACTS. Eur Heart J. 2016;37(38):2893–2962.
 17. Niessner A, Tamargo J, Morais J, et al. Reversal strategies for non-
vitamin K antagonist oral anticoagulants: a critical appraisal of available 
evidence and recommendations for clinical management-a joint position 
paper of the European Society of Cardiology Working Group on Cardio-
vascular Pharmacotherapy and European Society of Cardiology Work-
ing Group on Thrombosis. Eur Heart J. 2017;38(22):1710–1716.
Box 1 Reasonable indications for the use of idarucizumab in 
dabigatran-treated patients
intracranial bleeding
Life-threatening bleeding that cannot be controlled with local 
hemostatic measures
Major bleeding in patients with acute worsening of renal function 
resulting in severe acute renal insufficiency
Major bleeding with delayed elimination/clearance of dabigatran due 
to impaired renal function
Major bleeding with dabigatran overdosing
Need for urgent surgery or invasive interventions that carry a high 
risk of major bleeding and cannot be delayed
emergency surgery in major trauma
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
5.
18
5.
13
7.
52
 o
n 
13
-F
eb
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Therapeutics and Clinical Risk Management 2018:14submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1488
Proietti and Boriani
 18. Salzano A, Proietti M, D’Assante R, Saldamarco L, Cittadini A, 
Paladino F. Bleeding related to non-vitamin K antagonist oral anti-
coagulants in emergency department: A “Real-world” snapshot from 
Southern Italy. On behalf of MIRC-NOAC study group. Eur J Intern 
Med. 2018;48:e21–e24.
 19. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Con-
sensus Decision Pathway on Management of Bleeding in Patients on 
Oral Anticoagulants. J Am Coll Cardiol. 2017;70(24):3042–3067.
 20. Verma A, Ha ACT, Rutka JT, Verma S. What surgeons should know 
about non-vitamin K oral anticoagulants: A review. JAMA Surg. 2018; 
153(6):577.
 21. Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K 
antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273–281.
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
5.
18
5.
13
7.
52
 o
n 
13
-F
eb
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
